| Literature DB >> 32296088 |
Jane L Ward1, Yanqi Wu2,3, Claudia Harflett2, Hannah Onafuye4, Delia Corol2, Charlotte Lomax2, William J Macalpine2, Jindrich Cinatl5, Mark N Wass4, Martin Michaelis4, Michael H Beale6.
Abstract
Willow (Salix spp.) is well known as a source of medicinal compounds, the most famous being salicin, the progenitor of aspirin. Here we describe the isolation, structure determination, and anti-cancer activity of a cyclodimeric salicinoid (miyabeacin) from S. miyabeana and S. dasyclados. We also show that the capability to produce such dimers is a heritable trait and how variation in structures of natural miyabeacin analogues is derived via cross-over Diels-Alder reactions from pools of ortho-quinol precursors. These transient ortho-quinols have a role in the, as yet uncharacterised, biosynthetic pathways around salicortin, the major salicinoid of many willow genotypes.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32296088 PMCID: PMC7160102 DOI: 10.1038/s41598-020-63349-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Structures. Carbon numbering system and stereochemical depiction for salicin and salicortin follows that of Feistel et al.[2]. For clarity, and to reflect biosynthetic provenance, the salicinoid numbering has been maintained in the numbering of miyabeacin and derivatives.
Figure 2LC-MS data of NWC885 S. miyabeana in negative ion mode. (A) Total ion chromatogram of juvenile stem tissue; (B) Total ion chromatogram of juvenile leaf tissue. Numbered peaks are labelled according to the compound numbering in Fig. 1. Additional peaks labelled a-f are identified as follows: a: luteolin-7-glucoside; b: unknown; c: kaempferol acetyl glucoside isomer; d: kaempferol acetyl glucoside isomer; e: unknown; f: luteolin.
1H-NMR data (600 MHz, D2O:CD3OD (80:20) referenced to d4-TSP (0.01%) at δ0.00) for compounds 2, 3, 6 and 7. δin ppm; J in Hz.
| Position | 2 | 3 | 6 | 7 |
|---|---|---|---|---|
| 1 | — | — | — | |
| 2 | 7.22 (d, 8.1) | 7.19 (d, 8.3) | 7.20 (d, 8.2) | 7.19 (d, 8.0) |
| 3 | 7.43 (ddd, 8.0, 7.5, 1.9) | 7.41 (ddd, 8.0, 7.5, 2.0) | 7.43 (ddd, 8.5, 7.5, 1.5) | 7.40 (m) |
| 4 | 7.14 (dt, 7.3, 0.9) | 7.12 (t, 7.5)/ 7.11 (t, 7.5) | 7.12 (ddd, 7.5, 7.4, 0.9) | 7.12 (td, 7.5, 0.9) |
| 5 | 7.38 (dd, 7.5, 1.6) | 7.32 (dd, 7.6, 1.5) / 7.34 (dd, 7.6.1.5) | 7.35 (dd, 7.5, 1.5) | 7.31 (dd, 7.6, 1.5) |
| 6 | — | — | — | — |
| 7α | 5.42 (d, 12.2) | 5.40 (d, 11.9) | 5.46 (d, 11.7) | 5.39 (d, 11.9) |
| 7β | 5.27 (d, 12.2) | 5.19 (d, 11.9) | 5.13 (d, 11.7) | 5.18 (d, 11.9) |
| 8 | — | — | — | — |
| 9 | — | — | — | — |
| 10 | 5.76 (dt, 9.8, 1.6) | 3.59–3.63 (m) | 2.76 (dd, 4.4, 2.1) | 3.57–3.61 (m) |
| 11 | 6.27 (dt, 10.0, 3.7) | 3.58–3.55 (m) | 2.99 (m) | 3.48–3.53 (m) |
| 12 | 2.62–2.69 (m) & 2.51–2.57 (m) | 6.59 (dd, 10.2, 4.1) | 2.88 (m) | 6.63 (dd, 10.2, 4.1) |
| 13 | 2.88–2.94 (m) & 2.57–2.62 (m) | 6.02 (dd, 10.2, 1.5) | 3.12 (dd, 7.6, 4.0) | 6.02 (dd, 10.1, 1.7) |
| 14 | — | — | — | — |
| 15 | — | 3.50–3.53 (m) | 2.76 (dd, 4.4, 2.1) | 3.28–3.33 (m) |
| 16 | — | 6.19 (t, 7.9) | 2.99 (m) | 6.27 (ddd, 7.9, 6.9, 1.0) |
| 17 | — | 5.91 (ddd, 7.9, 6.5, 1.4) | 2.88 (m) | 5.94 (1 H, ddd, 7.9, 6.5, 1.4) |
| 18 | — | 3.43 (m) | 3.12 (dd, 7.6, 4.0) | 3.36 (1 H, ddd, 6.0, 2.4, 1.4) |
| 19 | — | — | — | — |
| 20 | — | — | — | — |
| 21 | — | — | — | — |
| 22β | — | 5.38 (d, 12.1) | 5.46 (d, 11.7) | — |
| 22α | — | 5.16 (d, 12.1) | 5.13 (d, 11.7) | |
| 23 | — | — | ||
| 24 | — | 7.32 (dd, 7.6, 1.5)/ 7.34 (dd, 7.6.1.5) | 7.35 (dd, 7.5, 1.5) | |
| 25 | — | 7.12 (t, 7.5)/7.11 (t, 7.5) | 7.12 (ddd, 7.5, 7.4, 0.9) | |
| 26 | — | 7.41 (ddd, 8.0, 7.5, 2.0) | 7.43 (ddd, 8.5, 7.5, 1.5) | |
| 27 | — | 7.20 (d, 8.3) | 7.20 (d, 8.2) | |
| 28 | — | — | ||
| 1′ | 5.10 (d, 7.6) | 5.09 (d, 7.5)/5.07 (d, 7.8) | 5.07 (d, 7.8) | 5.06 (d, 7.3) |
| 2′ | 3.56 (m) | 3.55–3.63 (m) | 3.51 (dd, 9.4, 7.8) | 3.49–3.59 (m) |
| 3′ | 3.57–3.62 (m) | 3.56–3.62 (m) | 3.58 (m) | 3.54–3.61 (m) |
| 4′ | 3.45–3.50 (m) | 3.47–3.52 (m) | 3.45 (t, 9.4) | 3.45–3.53 (m) |
| 5′ | 3.57–3.62 (m) | 3.56–3.62 (m) | 3.58 (m) | 3.54–3.61 (m) |
| 6′β | 3.74 (dd, 12.6, 5.9) | 3.77 (dd, 12.4, 6.0)/3.73 (dd, 12.4, 6.0) | 3.72 (dd, 12.4, 6.0) | 3.76 (dd, 12.5, 5.9) |
| 6′α | 3.92 (dd, 12.6, 2.4) | 3.94 (dd, 12.4, 2.1)/3.92 (dd, 12.4, 2.1) | 3.99 (dd, 12.5, 2.2) | 3.92 (dd, 12.4, 2.2) |
| 1″ | — | 5.09 (d, 7.5)/5.07 (d, 7.8) | 5.07 (d, 7.8) | |
| 2″ | — | 3.55–3.63 (m) | 3.51 (dd, 9.4, 7.8) | |
| 3″ | — | 3.56–3.62 (m) | 3.58 (m) | |
| 4″ | — | 3.47–3.52 (m) | 3.45 (t, 9.4) | |
| 5″ | — | 3.56–3.62 (m) | 3.58 (m) | |
| 6″β | — | 3.77 (dd, 12.4, 6.0)/3.73 (dd, 12.4, 6.0) | 3.72 (dd, 12.4, 6.0) | |
| 6″α | — | 3.94 (dd, 12.4, 2.1)/3.92 (dd, 12.4, 2.1) | 3.99 (dd, 12.5, 2.2) |
13C-NMR data for salicortin 2, miyabeacin 3, miyabeacin B 6 and miyabeanol 7. δin ppm.
| Position | 2 | 3 | 6 | 7 | 7 |
|---|---|---|---|---|---|
| 1 | 157.7 | 158.1 | 158.1 | 158.0 | 157.8 |
| 2 | 117.9 | 118.0 | 117.9 | 117.7 | 117.3 |
| 3 | 133.3 | 133.5/133.4 | 133.9 | 133.7 | 133.2 |
| 4 | 125.7 | 125.7/125.8 | 125.9 | 125.7 | 125.3 |
| 5 | 133.0 | 133.7/133.6 | 134.3 | 133.7 | 133.2 |
| 6 | 126.8 | 126.9 | 126.4 | 126.6 | 126.6 |
| 7 | 66.7 | 67.3 | 67.1 | 67.2 | 67.0 |
| 8 | 173.5 | 173.6 | 174.0 | 173.7 | 173.6 |
| 9 | 81.0 | 82.2 | 80.6 | 82.5 | 82.4 |
| 10 | 128.9 | 40.3 | 43.1 | 40.6 | 40.4 |
| 11 | 136.7 | 43.5 | 41.0 | 43.9 | 43.7 |
| 12 | 28.7 | 152.5 | 37.7 | 152.8 | 152.7 |
| 13 | 38.5 | 131.0 | 48.1 | 130.8 | 130.6 |
| 14 | 199.2 | 198.6 | 210.6 | 199.0 | 199.1 |
| 15 | — | 45.2 | 43.1 | 45.7 | 45.5 |
| 16 | — | 135.6 | 41.0 | 136.0 | 135.6 |
| 17 | — | 132.8 | 37.7 | 132.2 | 132.2 |
| 18 | — | 54.3 | 48.1 | 54.6 | 54.5 |
| 19 | — | 210.0 | 210.6 | 213.3 | 213.4 |
| 20 | — | 80.0 | 80.6 | missing | 81.4 |
| 21 | — | 173.3 | 174.0 | — | — |
| 22 | — | 66.7 | 67.1 | — | — |
| 23 | — | 126.7 | 126.4 | — | — |
| 24 | — | 133.7/133.6 | 134.3 | — | — |
| 25 | — | 125.7/125.8 | 125.9 | — | — |
| 26 | — | 133.5/133.4 | 133.9 | — | — |
| 27 | — | 117.8 | 117.9 | — | — |
| 28 | — | 157.8 | 158.1 | — | — |
| 1′ | 102.8 | 103.1/103.0 | 102.9 | 103.0 | 102.7 |
| 2′ | 75.9 | 76.1 | 76.0 | 76.0 | 75.8 |
| 3′ | 78.7 | 79.2 | 79.0 | 79.1 | 78.7 |
| 4′ | 72.2 | 72.5/72.4 | 72.8 | 72.4 | 72.2 |
| 5′ | 78.7 | 78.7/78.8 | 79.0 | 78.8 | 78.5 |
| 6′ | 63.4 | 63.7 | 63.9 | 63.6 | 63.5 |
| 1″ | — | 103.1/103.0 | 102.9 | — | — |
| 2″ | — | 76.1 | 76.0 | — | — |
| 3″ | — | 79.2 | 79.0 | — | — |
| 4″ | — | 72.5/72.4 | 72.8 | — | — |
| 5″ | — | 78.7/78.8 | 79.0 | — | — |
| 6″ | — | 63.7 | 63.9 | — | — |
IC50 assessment of miyabeacin 3 in six cancer cell lines.
| Cancer Type | Cell Line | Miyabeacin IC50 (μg/mL) |
|---|---|---|
| Breast | BT-474 | 27.04 |
| Oesophageal | COLO-680N | 5.08 |
| Ovarian | COLO-704 | 20.18 |
| Ovarian | EFO-21 | 12.69 |
| Breast | MCF-7 | 2.19 |
| Neuroblastoma | UKF-NB-3 | 7.12 |
Replicated IC50 determination of miyabeacin 3 in three cancer cell lines.
| Cancer Type | Cell Line | Miyabeacin IC50 Concentration (µg/mL) | IC50 (μM) | ||||
|---|---|---|---|---|---|---|---|
| Oesophageal cancer | COLO-680N | 5.08 | 15.08 | 51.46 | 23.87 | 19.93 | |
| Ovarian cancer | COLO-704 | 20.18 | 32.38 | 50.79 | 34.45 | 12.58 | |
| Neuroblastoma | UKF-NB-3 | 7.12 | 20.97 | 15.33 | 14.47 | 5.69 | |
Figure 3Concentration of miyabeacin, 3, miyabeacin B, 6 and miyabeanol, 7 in juvenile tissue of S. dasyclados and S. miyabeana accessions. (A) Leaf data; (B) Stem data.
Figure 4Quantified metabolite concentrations from NWC577 S. dasyclados grown in controlled conditions across a 60-day timecourse. Data is coloured according to harvest time with labelling representing the number of days post bud burst. (A) leaf data; (B) Pearson correlation coefficients for metabolite pairs; (C) stem data.
Figure 5The formation of miyabeacin, 3 via cyclodimerization of salicortenone, 4.
Figure 6Proposed biosynthetic scenarios leading to miyabeacin, 3 and downstream products.